NL-OMON43922已完成不适用
Brown adipose tissue activity and energy metabolism in cachexia induced by cancer or chronic disease - Brown adipose tissue activity and energy metabolism in cachexia
Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 70 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Cachectic pancreatic cancer patients:
- •* Stage I-IV pancreatic cancer patients;
- •* The diagnostic criterion for cachexia is unintentional weight loss more than 5% over the past 6 months or more than 2% in individuals with a body-mass index < 20 kg/m2 and muscle wasting assessed by DXA;
- •* Age * 30 years;
- •* Gender: male and female;
- •Cachectic NSCLC patients:
- •* Stage I-IV NSCLC patients;
- •* The diagnostic criterion for cachexia is unintentional weight loss more than 5% over the past 6 months or more than 2% in individuals with a body-mass index < 20 kg/m2 and muscle wasting assessed by DXA;
- •* Age * 30 years;
- •* Gender: male and female;;Cachectic COPD patients:
- •* COPD GOLD I-IV (COPD patients with and without receiving lung volume reduction by endobronchial valves);
- •* The diagnostic criterion for cachexia is unintentional weight loss more than 5% over the past 6 months or more than 2% in individuals with a body-mass index < 20 kg/m2 and muscle wasting assessed by DXA;
- •* Age * 30 years;
- •* Gender: male and female;;Non-cachectic COPD patients:
- •* COPD GOLD I-IV (COPD patients with and without receiving lung volume reduction by endobronchial valves);
- •* Age * 30 years;
- •* Gender: male and female;;Healthy individuals:
- •* Age * 30 years;
- •* Gender: male and female;;Emphysematous COPD patients:
- •* Receiving lung volume reduction by endobronchial valves
- •* Age * 30 years;
- •* Gender: male and female;
排除标准
- •Cachectic pancreatic cancer patients:
- •* Uncontrolled Diabetes Mellitus;
- •* Patients with severe clotting disorder;
- •* Patients with an active second malignancy;
- •* Psychological unstable persons presumed unfit to perform the measurements, including claustrophobia;
- •* Persons unable to lie or sit still for 1-2 hours;
- •* Oxygen therapy;
- •* Pregnant subjects;
- •* Subjects unable to undergo MRI (e.g. pacemaker; neurostimulator; ICD or leads; Foley bladder catheter; medication pump; cochlear or hearing implant; tattoos or other items that cannot be removed and include metal parts (for instance from operations in the past); metal splinter in the eye; vascular clips; denture, which contains magnets);
- •* Subjects that received high doses of radiotherapeutic radiation of the neck and/or upper chest in their medical history;
- •* Persons that received cervical or thoracic sympathectomy or have a nerve dysfunction which is likely to influence sympathetic nerves;
- •* The use of medication that influences the sympathetic nerve system: ß-blockers, *-blockers, central anti-hypertensives, certain anti-depression drugs (MAO inhibitors, tricyclic anti-depressives), reserpine, cocaïne, calciumblockers, labetalol, and certain tranquillizers (fenothiazines).;Cachectic NSCLC patients:
- •* Uncontrolled Diabetes Mellitus;
- •* Patients with severe clotting disorder;
- •* Patients with an active second malignancy;
- •* Psychological unstable persons presumed unfit to perform the measurements, including claustrophobia;
- •* Persons unable to lie or sit still for 1-2 hours;
- •* Oxygen therapy;
- •* Pregnant subjects;
- •* Subjects unable to undergo MRI (e.g. pacemaker; neurostimulator; ICD or leads; Foley bladder catheter; medication pump; cochlear or hearing implant; tattoos or other items that cannot be removed and include metal parts (for instance from operations in the past); metal splinter in the eye; vascular clips; denture, which contains magnets);
- •* Subjects that received high doses of radiotherapeutic radiation of the neck and/or upper chest in their medical history;
- •* Persons that received cervical or thoracic sympathectomy or have a nerve dysfunction which is likely to influence sympathetic nerves;
- •* The use of medication that influences the sympathetic nerve system: ß-blockers, *-blockers, central anti-hypertensives, certain anti-depression drugs (MAO inhibitors, tricyclic anti-depressives), reserpine, cocaïne, calciumblockers, labetalol, and certain tranquillizers (fenothiazines).;Cachectic COPD patients:
- •* Uncontrolled Diabetes Mellitus;
- •* Patients with severe clotting disorder;
- •* Patients with an active second malignancy;
- •* Psychological unstable persons presumed unfit to perform the measurements, including claustrophobia;
- •* Persons unable to lie or sit still for 1-2 hours;
- •* Oxygen therapy;
- •* Pregnant subjects;
- •* Subjects unable to undergo MRI (e.g. pacemaker; neurostimulator; ICD or leads; Foley bladder catheter; medication pump; cochlear or hearing implant; tattoos or other items that cannot be removed and include metal parts (for instance from operations in the past); metal splinter in the eye; vascular clips; denture, which contains magnets);
- •* Subjects that received high doses of radiotherapeutic radiation of the neck and/or upper chest in their medical history;
- •* Persons that received cervical or thoracic sympathectomy or have a nerve dysfunction w
研究者
相似试验
招募中
不适用
Activity of brown adipose tissue and characteristics of physical function in humansobesity or type 2 diabetesJPRN-UMIN000029276Kanazawa University Graduate School of Medical Sciences30
已完成
不适用
Activation of brown adipose tissue in lean and obese meObesityNL-OMON39965Academisch Medisch Centrum23
进行中（未招募）
不适用
Influence of body fat in energy expenditure of People living with HIV and AidsRBR-4zrmm4Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
已完成
不适用
Brown Adipose Tissue in Type 1 DiabetesType1diabetesNCT02984514Per-Ola Carlsson11
招募中
不适用
A study on energy-burning effect of brown fat in humansMetabolic and Endocrine - Metabolic disordersDiet and Nutrition - ObesityMetabolic and Endocrine - DiabetesObesityDiabetesACTRN12615000688583Garvan Institute of Medical Research30